Messages from ASCO


Targeted combination therapies seem to be what’s coming out of the recent ASCO conference in Atlanta. This seems to be a natural progression from the Gleevec, Erbitux, and Herceptin phase of cancer drugs, to which cancers are can become resistant. (Luckily, as Derek Lowe points out in the linked blog entry, at least resistance doesn’t spread from person to person.)

Advertisements

One Response

  1. Test title…

    This is an example….

Comments are closed.

%d bloggers like this: